DailyIQ
Last updatedjust now

ROP·Roper Technologies, Inc.

$362.28
-1.10 (-0.30%)
Overnight$362.28+0.00 (+0.00%)
High
$368.85
Open
$360.98
Market Cap
35.86B
52W High
$521.28
Low
$359.07
P. Close
$362.28
P/E
14.32
52W Low
$305.96
Fwd P/E
14.86
DailyIQ Est.
$445.88
Inst. Ownership
47.5%
Short Interest
5.26%
Days to Cover
8.3
Technical Score (1D)
27
BEARISH
News Sentiment
54
MIXED
On Oct 5, Roper Technologies was described as becoming more attractive after a recent valuation compression. Analysts noted that the company’s focus on specialized software for industries such as healthcare, insurance, education, and water infrastructure provides strong customer lock‑in and cash generation. The valuation shift was seen as a positive catalyst, suggesting improved upside potential for investors. Roper’s ability to deploy excess cash into acquisitions, share buybacks, and dividends was cited as a key strength. The report highlighted that the valuation compression had increased the company’s attractiveness to investors.
LOW TARGET
$335 -7.5%
2 analysts
MEAN TARGET
$439 +21.3%
16 analysts
HIGH TARGET
$550 +51.8%
9 analysts
PRICE RANGE
$335.00 - $550.00
SB / B / H / S / SS
6/6/12/2/1
DAILYIQ EST.
$445.88 (+23.1%)
Sector
Technology
Industry
Software - Application
Exchange
NMS
Country
United States
Symbol
ROP
Description
Roper Technologies, Inc. is a global developer of vertical software and technology-enabled products, serving diverse markets across North America, Europe, and Asia. The company's core strategy centers around providing specialized software solutions for sectors like healthcare, education, and financial services, alongside technology-driven products such as medical devices and measurement systems. Roper’s value proposition lies in its ability to offer tailored solutions that streamline operations, improve efficiency, and enhance decision-making for its customers. With a distribution network encompassing direct sales, resellers, and distributors, Roper Technologies aims to deliver its products and services to a broad customer base. Originally established in 1981 and headquartered in Florida, the company has evolved to meet the changing needs of its various target industries.
Bought (1Y)
0 shares
$0
Sold (1Y)
8,434 shares
$3.1M
Dubey Abhijit-
Award/Grant13 shares2026-10-01
Dubey Abhijit-
Award/Grant619 shares2026-10-01
ARCHAMBEAU SHELLYE L-
Award/Grant84 shares2026-09-15
ESTEVES IRENE M-
Award/Grant78 shares2026-09-15
Joyce Thomas Patrick JR-
Award/Grant78 shares2026-09-15
82/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
69.2%
Net Margin
19.4%
Revenue CAGR
7.6%
Current Ratio
0.52x
Debt / Equity
0.47x
Return on Equity
7.7%
Earnings Summary
Roper Technologies, Inc. is a global developer of vertical software and technology‑enabled products, serving markets such as healthcare, education, and financial services with specialized software solutions and measurement systems. Operating within the technology sector and the software‑application industry, Roper focuses on delivering tailored solutions that streamline operations and enhance decision‑making for its diverse customer base. In the most recent four quarters, Roper’s earnings per share (EPS) have shown a steady upward trajectory, rising from $4.81 in Q4 2024 to $5.14 in Q3 2025, while revenue grew from $1.877 billion to $2.018 billion, reflecting a consistent acceleration in top‑line growth. The company has consistently beat analyst estimates in each of the last four quarters, with EPS exceeding expectations by a narrow margin in Q1 2025 and Q2 2025, and maintaining a positive revenue trend even in Q4 2025 where revenue fell slightly below the $2.101 billion estimate. Historically, Roper has delivered double‑digit year‑over‑year revenue growth for the past three years, with EPS growth remaining positive but modest, indicating a stable profitability profile. Recent news highlights the addition of Abhijit Dubey, former CEO and Chief AI Officer of NTT DATA, to Roper’s Board of Directors, signaling a strategic push toward AI and cloud integration across its product portfolio; while no immediate financial impact was disclosed, the governance upgrade may support future earnings momentum.

EPS

EstBeatMiss
$4.69$5.00$5.31$5.62$5.93Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$5.79 - -
Q2'26$5.66$5.38-4.9%
Q1'26$5.30$5.16-2.7%
Q4'25$5.19$5.21+0.4%
Q3'25$5.11$5.14+0.6%
Q2'25$4.83$4.87+0.8%

Revenue

EstBeatMiss
$1.9B$2.0B$2.1B$2.2B$2.2BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.2B - -
Q2'26$2.1B$2.1B-0.4%
Q1'26$2.1B$2.1B-0.3%
Q4'25$2.1B$2.1B-2.1%
Q3'25 - $2.0B -
Q2'25 - $1.9B -

Market Data

ROP Stock Snapshot

BEARISH27/100
$362.28+$0.00 (0.0%)
Market cap
35.86B
P/E ratio
14.3
Day range
$359.07 – $368.85
News sentiment
54/100 · Neutral
Analyst target
$439.43 (+21.3%)
Consensus
Hold · 27 analysts
52-week range+18.4% off low · -30.5% from high
$305.96$521.28
Price $362.28 DailyIQ Est. $445.88

The chart on ROP has not stabilised: price is in the lower half of its 52-week range and the trend is still down. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Behaviour On Record

What ROP's own history says about today's numbers

Realized volatility (21d)
28.1% 86th pct
Below its peak
-38.8%
vs 200-day average
-1.5%
Up days (1y)
53%

Roper Technologies, Inc. is currently running 28.1% annualised volatility over the last 21 sessions. Measured against ROP's own 13 years of daily returns rather than a market-wide average, that is the 86th percentile — elevated for this stock, against a typical reading of 17.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ROP is trading -38.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -14.6%, and the deepest was -35.2% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -1.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 24th percentile — a narrower gap than it typically runs. Over the past year ROP closed higher on 53% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, ROP finished the month higher 6 of 13 times, with a median return of -1.9% and an average of +1.5%. Its strongest month historically has been November at +4.1% on average, its weakest September at -3.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ROP has opened more than 2% away from the prior close in 67 of 3,267 sessions (2.1% of the time), with the largest gaps running +9.7% and -23.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ROP moved an average of 2.8% in the session after earnings, closing higher 1 of those 3 times, with a median move of -2.4% and a largest of +3.5%.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against ROP's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ROP's sector?

Roper Technologies, Inc. sits in the Software sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Software industry group, ROP ranks 2nd of 15 tracked industries, leading.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
100
Industry rank
#2 of 15

Options Market

What is the options market pricing for ROP?

CallsPuts

For Roper Technologies, Inc.'s nearest expiry (2026-11-20, 44 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.92), with at-the-money implied volatility around 1.6%. The options market is pricing roughly a ±0.5% move by that expiry — a range of about $364.25–$368.22.

Put/call ratio (2026-11-20)
0.92
ATM implied volatility
1.6%
Total open interest
48
Expected move by 2026-11-20
±0.5% ($364.25–$368.22)

Analyst Rating Changes

Are analysts turning bullish or bearish on ROP?

RBC Capital most recently reiterated its rating on Roper Technologies, Inc. to Sector Perform on Aug 18, 2026 with a price target of $417. Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
RBC Capital — Sector Perform
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Aug 18, 2026RBC CapitalReiteratedSector Perform$417
Aug 6, 2026Argus ResearchUpgradeHold → Buy$450
Jul 29, 2026JP MorganMaintainedUnderweight$397 → $415
Jul 24, 2026RBC CapitalMaintainedSector Perform$407 → $417
Jul 24, 2026Piper SandlerMaintainedOverweight$540 → $526
Jul 10, 2026BMO CapitalInitiatedMarket Perform$393
Apr 24, 2026BarclaysMaintainedUnderweight$380 → $373
Apr 24, 2026RBC CapitalMaintainedSector Perform$393 → $407
Apr 24, 2026BairdMaintainedOutperform$464 → $470
Apr 24, 2026Piper SandlerMaintainedOverweight$530 → $540
Apr 1, 2026BarclaysMaintainedUnderweight$409 → $380
Jan 29, 2026Goldman SachsMaintainedNeutral$507 → $440

ROP Competitive Positioning

Roper Technologies, Inc. (ROP) is tracked alongside these names in Software - Application on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

54/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Roper Technologies (ROP) was highlighted on October 5 as becoming more attractive following a recent valuation compression. Analysts noted that ROP’s focus on specialized software for industries such as healthcare, insurance, education, and water infrastructure provides strong customer lock‑in and cash generation. The company’s ability to deploy excess cash into acquisitions, share buybacks, and dividends was cited as a key strength. The valuation shift was seen as a positive catalyst, suggesting improved upside potential for investors.
What did this article say?
Roche Holding received FDA acceptance of its New Drug Application for fenebrutinib under priority review for multiple sclerosis. The oral BTK inhibitor targets both relapsing and primary progressive forms, potentially becoming the first high‑efficacy oral therapy addressing relapse control and disability progression. The priority review underscores Roche’s focus on neuroscience and autoimmune pipelines, positioning fenebrutinib as a key growth driver within its broader drug portfolio.
What did this article say?
Roper Technologies (ROP) was forecast to report its third‑quarter 2026 earnings shortly after the publication date. Analysts projected a double‑digit percentage increase in net income, suggesting stronger profitability than the previous quarter. The guidance implied continued operational momentum across ROP’s diversified industrial segments. No significant risks or headwinds were highlighted in the forecast. The positive outlook reflects confidence in ROP’s revenue and cost management strategies.
What did this article say?
Roper Technologies announced on October 1 that Abhijit Dubey, CEO and Chief AI Officer of NTT DATA, joined its Board of Directors. Dubey brings extensive experience in AI strategy and digital transformation from his leadership roles at NTT DATA and NTT Ltd. His appointment is expected to strengthen Roper’s focus on AI-driven solutions and enhance its competitive positioning in technology services. The move signals the company’s intent to deepen its AI capabilities and support future growth initiatives. No immediate financial impact was disclosed, but the addition is viewed as a strategic enhancement.
What did this article say?
Roper Technologies announced that its third‑quarter 2026 earnings will be released before the market opens on October 22, 2026, and scheduled a conference call at 8:00 AM ET to discuss the results. The call will be available via webcast and telephone, with materials posted in the Investors section of the company’s website. The announcement provided the date and logistics for investors to review the upcoming financial data.
What did this article say?
Roche Diagnostics subsidiary TIB MOLBIOL launched the LightMix® Newborn TREC/SMN1/HBB kit, a CE‑marked in‑vitro diagnostic test that simultaneously screens newborns for spinal muscular atrophy, severe combined immunodeficiency, and sickle cell disease. The kit offers a ready‑to‑use solution that integrates into existing laboratory workflows, enabling earlier detection and treatment of these severe conditions. The announcement expands Roche’s early diagnostics portfolio and positions the company to capture a growing market for newborn screening in countries accepting the CE mark.
What did this article say?
Roche Holding (ROP) announced new research collaborations focused on AI‑powered therapeutics and metabolic disease programs in late September 2026. The company signed a partnership with Earendil Labs to apply AI to bispecific antibody cancer therapies across multiple tumor types, and a collaboration with Atavistik Bio to develop allosteric small molecules for cardiovascular, renal and metabolic conditions. Enicepatide (CT‑388) reported positive Phase 2 results in type 2 diabetes and obesity, underscoring ROP’s GLP‑1/GIP pipeline ambitions. These developments represent a material positive driver for ROP’s R&D pipeline and potential future revenue streams.
What did this article say?
Roche Holding (ROP) achieved a primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, with its partner Ionis’s drug sefaxersen significantly reducing proteinuria versus placebo. The milestone adds a strong clinical driver to ROP’s already robust share price performance, which has risen over 11% YTD. The win reinforces ROP’s positioning in the nephrology pipeline and may support future pricing and reimbursement prospects.
What did this article say?
Roche Holding (ROP) announced that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide achieved its primary endpoint in relapsed or refractory follicular lymphoma. The positive results support regulatory filings to broaden Lunsumio’s indication to patients who have received at least one prior systemic therapy. The combination’s outpatient administration design could reduce hospital capacity strain, adding a practical benefit to the therapeutic profile. This milestone is a material upside for ROP, potentially driving a rally in the stock and strengthening its oncology pipeline narrative.

Technical Analysis

Real-time indicators across multiple timeframes

27
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $17.03B combined position · 10 adding, 14 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy12,477,10012.60%$5.55B2026-01-29
BlackRock, Inc.▲ Buy9,890,6949.99%$3.35B2026-08-07
Invesco Ltd.▲ Buy4,270,3214.31%$1.45B2026-08-14
Geode Capital Management, LLC▲ Buy3,118,3423.15%$1.05B2026-08-12
Wellington Management Group LLP▼ Sell2,631,0702.66%$890.33M2026-08-14
Norges Bank▼ Sell2,074,2722.10%$701.91M2026-08-12
Harris Associates L P▲ Buy1,974,3251.99%$668.09M2026-08-14
Morgan Stanley▼ Sell1,335,8431.35%$452.04M2026-08-13
Akre Capital Management LLC▼ Sell1,176,5621.19%$398.14M2026-08-14
Goldman Sachs Group Inc▲ Buy1,090,6941.10%$369.08M2026-08-14
Northern Trust Corp▼ Sell974,9670.98%$329.92M2026-08-13
JPMorgan Chase & Co▼ Sell830,0020.84%$277.88M2026-08-12
Ruane, Cunniff & Goldfarb L.P.• Hold674,9020.68%$228.38M2026-08-14
AllianceBernstein L.P.▲ Buy559,7430.57%$198.07M2026-08-14
D. E. Shaw & Co., Inc.▼ Sell522,8070.53%$176.91M2026-08-14
Bank of America Corp▼ Sell490,3470.50%$165.93M2026-08-14
Wells Fargo & Company▼ Sell363,6230.37%$123.05M2026-08-14
Citigroup Inc▲ Buy334,0400.34%$113.04M2026-08-03
Loomis Sayles & Co L P▼ Sell294,5860.30%$99.68M2026-08-14
Renaissance Technologies LLC▼ Sell204,7000.21%$91.12M2026-02-12
FMR LLC (Fidelity)▼ Sell231,1290.23%$78.21M2026-08-13
Gotham Asset Management, LLC▲ Buy209,9530.21%$71.05M2026-08-14
Millennium Management LLC▲ Buy197,3370.20%$66.78M2026-08-14
AQR Capital Management LLC▼ Sell192,1230.19%$64.45M2026-08-14
Neuberger Berman Group LLC▼ Sell183,4650.19%$62.08M2026-08-13
Q2 2026 flow:3.95M sh bought ($1.34B)3.40M sh sold ($1.14B)net +553.5K sh (+$192.65M)
Congressional Trading Activity
8 disclosed trades · ~$113.0K est. traded value · 4 buys, 4 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-04-142026-05-08
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-03-132026-04-07
Jared MoskowitzHouseFL23▼ Sell$1K - $15K2026-02-272026-03-30
Gilbert CisnerosHouseCA31▼ Sell$15K - $50K2026-02-102026-03-09
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-08-042025-09-12
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-222025-08-13
Susan M. CollinsSenateME▲ Buy$15K - $50K2014-11-102014-12-01
Susan M. CollinsSenateME▲ Buy$1K - $15K2014-06-192015-07-20